Genitourinary Cancers

Sumanta Kumar Pal, MD, a medical oncologist at City of Hope, discusses the clinical utility of PD-L1 in metastatic renal cell carcinoma (mRCC).

Jonathan L. Wright, MD, MS, FACS, highlights the available therapies for patients with localized muscle-invasive bladder cancer.

Robert A. Figlin, MD, director, Division of Hematology/Oncology, Steven Spielberg Professor of Biomedical Sciences and Medicine, Cedars-Sinai Medical Center, discusses considerations when combining TKIs and immunotherapy agents in the management of advanced renal cell carcinoma.

Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses concerns with immune-related adverse events (irAEs) in renal cell carcinoma (RCC).

Immune checkpoint inhibitors, with their favorable safety and antitumor activity profiles, have heralded a new era in urothelial carcinoma treatment.

The investigational mitomycin formulation UGN-101 demonstrated a 57% complete response rate in patients with low-grade upper-tract urothelial cancer.

Joaquim Bellmunt, MD, PhD, provides insight on how to navigate the complex treatment paradigm of metastatic bladder cancer.

Bradley G. Somer, MD, an associate professor of hematology/oncology and head of strategic expansion/development at the University of Tennessee West Cancer Center, discusses treatment selection considerations in renal cell carcinoma (RCC).

Joaquim Bellmunt, MD, PhD, genitourinary oncologist, Beth Israel Deaconess Medical Center, associate professor of medicine, Harvard Medical School, differentiates between immunotherapy options available for the treatment of patients with in bladder cancer.

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses second-line therapy selection in metastatic renal cell carcinoma.

Heather Greene, NP, discusses the importance of open communication between patients and providers from the onset of therapy and provided insight on the management of treatment-related adverse events in metastatic renal cell carcinoma.

Bradley G. Somer, MD, discusses the potential of combination regimens for patients with metastatic renal cell carcinoma.

Toni K. Choueiri, MD, discusses recent progress in RCC and where future research is heading in the field.

Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses sequencing in renal cell carcinoma (RCC).

Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses mechanisms of immune response in bladder cancer.

Daniel J. George, MD, discusses the status of treatment for patients with high-risk stage III RCC, as well as the role of sunitinib (Sutent) and checkpoint inhibitors in the RCC paradigm.

Sumanta Kumar Pal, MD, a medical oncologist at City of Hope, discusses developments made in frontline treatment for patients with metastatic renal cell carcinoma (mRCC).

Paul R. Eber, MD, discusses how the findings from CARMENA impact metastatic renal cell carcinoma treatment and what challenges remain.

Thomas Powles MBBS, MRCP, MD, discusses the changes to the frontline landscape of bladder cancer and where research should focus moving forward.

Paul Eber, MD, urologist, The Conrad Pearson Clinic, discusses the utility of cytoreductive nephrectomy in metastatic renal cell carcinoma (mRCC).

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses next steps for treatment in renal cell carcinoma.

Vivek Venkatramani, MD, and Dipen J. Parekh, MD, discuss the evolution of surgery in bladder cancer.

Newer immunotherapy agents are changing traditional strategies for care, resulting in higher levels of collaboration.

Heather Greene, a nurse practitioner at West Cancer Center, discusses common treatment-related toxicities in metastatic renal cell carcinoma (RCC).

Although he held a longtime fascination with space exploration to the moon and Mars, Daniel P. Petrylak, MD, took a different path and broke new ground in another frontier: genitourinary oncology.